American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate

Senchyna, A.; Simon, Stéphane; Cissé, H.; Ginouvès, Marine; Prévot, Ghislaine; Alcoba, Gabriel; Demar, Magalie; Couppié, Pierre; Blaizot, Romain

doi:10.1111/bjd.18964

Cited by 14 publications

(21 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though AmBisome ® shows at least a 95% cure rate for visceral leishmaniasis (VL) in the Indian subcontinent and in Southern Europe [ 4 ], clinical data for New World CL are scarce. Moderate efficacies with a cure rate lower than 80% have been reported [ 5 , 6 , 7 ]. The use of AmBisome ® is also limited by systemic side effects, most frequently acute infusion-related events and nephrotoxicity [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes

et al. 2022

View full text Add to dashboard Cite

Liposomal amphotericin B (AmB) or AmBisome® is the most effective and safe therapeutic agent for visceral leishmaniasis (VL), but its clinical efficacy is limited in cutaneous leishmaniasis (CL) and HIV/VL co-infection. The aim of this work was to develop a formulation of AmB in PEGylated liposomes and compare its efficacy to AmBisome® in a murine model of CL. Formulations of AmB in conventional and PEGylated liposomes were characterized for particle size and morphology, drug encapsulation efficiency and aggregation state. Those were compared to AmBisome® in Leishmania amazonensis-infected BALB/c mice for their effects on the lesion size growth and parasite load. The conventional and PEGylated formulations showed vesicles with 100–130 nm diameter and low polydispersity, incorporating more than 95% of AmB under the non-aggregated form. Following parenteral administration in the murine model of CL, the PEGylated formulation of AmB significantly reduced the lesion size growth and parasite load, in comparison to control groups, in contrast to conventional liposomal AmB. The PEGylated formulation of AmB was also effective when given by oral route on a 2-day regimen. This work reports for the first time that PEGylated liposomal AmB can improve the treatment of experimental cutaneous leishmaniasis by both parenteral and oral routes.

show abstract

Section: Introductionmentioning

confidence: 99%

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The treatment response rate is variable, in the range of 72%-88% in some studies of Old World and New World species; more recent studies have described response rates as low as 46% when looking at clinical cure at 90 days and 63% when delayed healing and a second course of liposomal amphotericin B were included. [23][24][25][26][27][28][29] In our study, 30% of patients who received liposomal amphotericin B had adverse events, with acute kidney injury being the most common (50%). Rates of adverse events with liposomal amphotericin B in the treatment of cutaneous leishmaniasis have been reported to be as high as 46%-53%.…”

Section: Discussionmentioning

confidence: 58%

Cutaneous leishmaniasis in travellers and migrants: a 10-year case series in a Canadian reference centre for tropical diseases

Lemieux

Lagacé

Billick

et al. 2022

cmajo

View full text Add to dashboard Cite

Cutaneous and mucosal leishmaniasis are protozoan infections transmitted by the bite of female sandflies. This tropical disease affects 700 000 to 1 million new individuals annually. 1 Close to 20 species of Leishmania, belonging to 2 main subgenera (Leishmania and Viannia), are involved in human leishmaniasis. Cases of cutaneous leishmaniasis mainly occur in the Americas (New World leishmaniasis), as well as in the Mediterranean basin, the Middle East and Central Asia (Old World leishmaniasis).The clinical presentation of cutaneous leishmaniasis depends on various factors, including the acquired species, strains and virulence factors, as well as host characteristics, such as age, gender and immune status. 2,3 The lack of awareness of this disease among physicians in nonendemic countries, as well as varied clinical manifestations, may result in delayed diagnosis. 4

show abstract

“…They have a high cure rate, but the treatment is long, with frequent adverse events (25% patients require treatment discontinuation), and regular clinical, cardiac and laboratory monitoring is mandatory [16]. L-AmB and Sb v show comparable efficacy for treatment of complex CL [17]. However, L-AmB treatment is a 5 day course therapy, compared with the 3 week course treatment with Sb v drugs.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B

et al. 2021

View full text Add to dashboard Cite

Background: There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. Methods: We performed a retrospective study in Vall d’Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. Results: The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. Conclusions: L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects.

show abstract

American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate

Cited by 14 publications

References 9 publications

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes

Cutaneous leishmaniasis in travellers and migrants: a 10-year case series in a Canadian reference centre for tropical diseases

Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B

Contact Info

Product

Resources

About